Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VVN001 in Chinese Subjects With Dry Eye Disease
NCT06360133Phase 3Recruiting
- Sponsor
- VivaVision Biotech
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing VVN001 Ophthalmic Solution, 5% with Vehicle Ophthalmic Solution (2 arms). Primary endpoint: Corneal Fluorescein Staining at Day 84. Started Apr 2024; status: recruiting.
02
Drugs
VVN001
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06360133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360133.